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1. Introduction 
Central nervous system (CNS) cancers are the second most frequent malignancy in 
childhood and the most common solid tumor in this age group. In recent years, significant 
advances in surgery, radiotherapy, and chemotherapy have favorably impacted survival for 
children with these tumors. However, a significant proportion of patients with CNS tumors 
suffer progress disease despite such treatment. Advances in the understanding the nature of 
the blood-brain/tumor barrier, chemotherapy resistance, tumor biology, and the role of 
angiogenesis and other signaling pathways in tumor progression and metastases have led to 
the advent of newer therapeutic strategies that circumvent these obstacles or target specific 
receptors that control signal transduction and/or angiogenesis in tumor cells. Ongoing 
clinical trials will determine if these novel modalities of treatment will improve the outcome 
of children with brain tumors.  
1.1 Epidemiology of pediatric brain tumors 
An estimated 2400 children between the ages of 0-19 years are diagnosed with invasive 
primary central nervous system (CNS) tumors in the United States each year. (Bleyer 
1999; Gurney, Smith et al. 1999) The incidence of CNS tumor in children < 20 years is 4.58 
per 100,000 person years (CBTRUS report, 2009). Brain tumors are second only in 
frequency to acute lymphoblastic leukemia (ALL) in children. Pilocytic astrocytomas 
((0.79 per 100,000 person-years) malignant glioma (0.51 per 100,000 person-years), and 
medulloblastoma (0.49 per 100, 000 person-years) are the commonest tumors (Figure 1) 
(Gurney, Smith et al. 1999). The incidence of low-grade astrocytomas, PNET, and 
ependymoma is inversely proportional to age while that of malignant glioma is relatively 
constant between birth to < 20 years (Bleyer 1999). The incidence of CNS tumors in 
children was found to have increased by 35% between the years 1975-84 (Smith, Freidlin 
et al. 1998). This increase has been mainly attributed to the introduction of magnetic 
resonance imaging (MRI) in the 1980s that improved detection of low grade tumors 
previously unidentifiable by other less optimal imaging modalities (Smith, Freidlin et al. 
1998). Brain growth occurs rapidly during early gestation and peaks around 4 months 
after birth but continues until 2-3 years thereafter (Baldwin and Preston-Martin 2004). 
Hence,  it is more vulnerable to genotoxic damage and neoplastic transformation than any 
other organ in the body due to its relatively longer course of development both in utero 
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and post -natal life during which the rapidly dividing cells become susceptible to 
exposure to potential environment toxins and DNA damage (Baldwin and Preston-Martin 
2004). 
In addition, it appears that fetal brain is less able to efficiently repair DNA alkylation 
induced by various mutagenic agents. The blood-brain barrier (discussed further below) 
is also not complete in the fetal brain and facilitates free transfer of carcinogens into the 
vulnerable neural tissue (Baldwin and Preston-Martin 2004). While hereditary genetic 
syndromes do cause a proportion of pediatric brain tumors, it is distinctly rare. Only 
about 5% of CNS malignancies are the direct consequence of a specific gene defect (Table 
1). However, in the majority of sporadic brain tumors, the factors that incite neoplastic 
transformation are largely unknown but are likely to be multi-factorial due to an inter 
play of both genes and the environment. One known environmental cause of brain 
tumors is ionizing radiation and can induce both benign and malignant gliomas or 
occasionally primitive neuro-ectodermal tumors (PNET) (Ron, Modan et al. 1988) 
(Hader, Drovini-Zis et al. 2003). Ron et al., reported a 33.1 relative risk (RR) of 
developing nerve sheath tumors of the head and neck in children who had received up 
to 600 cGy of irradiation for tinea captis infection in the 1950s (Ron, Modan et al. 1988). 
There was a lower but excess incidence of both meningiomas  (RR 9.5) and malignant 
gliomas (RR 2.6) as well in this cohort.  In recent years, radiation exposure is solely due 
to therapeutic irradiation of the brain for CNS leukemia or brain tumors and has been 
associated with a 22-fold risk of developing secondary brain tumors (mostly 
glioblastoma multiforme) especially in children less than 5 years at diagnosis (Neglia, 
Meadows et al. 1991). The role of other environmental toxins is relatively unclear 
(Gurney, Smith et al. 1999).  
2. Factors that contribute to treatment failure in children with brain tumors 
Although the annual mortality rate for pediatric cancers has steadily decreased over the 
last two decades, the proportion of deaths from CNS tumors in the same population has 
increased from 18% to 30% (Bleyer 1999). These figures clearly highlight the suboptimal 
outcomes in children with CNS malignancies compared to other pediatric tumors.  
Surgery, chemotherapy, and radiotherapy have long been established as treatment 
modalities for patients with brain tumors. It has also become obvious that a significant 
proportion of brain tumor patients suffer progressive disease during or following 
cytotoxic therapy. The causes for such therapeutic failure have been have been attributed 
to the presence of the blood-tumor barrier and drug or radio- resistance.(Groothuis 2000; 
Bredel 2001)The refractoriness of brain tumors to cytotoxic therapy stems from a 
multitude of factors that can be broadly classified as apparent or inherent cellular 
resistance (Bredel 2001; Scotto and Bertino 2001). Apparent resistance to a cytotoxic agent 
is usually due to the presence of the blood-brain barrier (BBB) (Groothuis 2000), the cell 
kinetics of a large tumor that has a smaller growth fraction (larger number of cells in the 
G0 fraction of the cell cycle), and hypoxic areas that limits the effect of cytotoxic therapy 
(Scotto and Bertino 2001). Inherent resistance can be either de novo or acquired. The 
various mechanisms of resistance to cytotoxic agents that are typically used in brain 
tumors are listed in Table 2.  
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*incidence rates by histologic group and sexage <20, all races, SEER1990-95 
Fig. 1. Malignant CNS tumor age-adjusted 
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SYNDROME GENE CHROMOSOME TUMORS 
Neurofibromatosis 
Type I 
NF-1 17q11 
Optic Gliomas 
Astrocytomas 
Neurofibromas 
Neurofibromatosis 
Type II 
NF-2 22q12 
Vestibular schwannomas 
Meningiomas 
Spinal cord ependymomas 
Von Hippel Lindau VHL 3p25 
Cerebellar 
hemangioblastomas 
Tuberous Sclerosis 
TSC1 and 
TSC2 
9q34 and 16p13 
Subependymal Giant Cell 
Astrocytoma 
Turcot 
APC 
 
MLH1 
PMS-2 
5q21
 
3p21 
7p22
Medulloblastoma 
Colorectal polyps 
Glioblastoma multiforme 
Colorectal polyps 
Gorlin PTCH 9q31 
Medulloblastoma 
Basal Cell Carcinoma 
Ovarian Fibromas 
Li- Fraumeni P53 17p13 
Astrocytoma 
PNET 
Soft tissue sarcoma 
Breast Carcinoma 
Leukemia 
Table 1. Common Genetic Syndromes and associated tumors 
 
 
Table 2. Mechanisms of cellular drug resistance in brain tumors. 
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Distribution No. of patients (%)  (of n = 713)* 
  
Tumor location  
Cerebellar hemisphere 225 (32%) 
Cerebral hemisphere 197 (28%) 
Midline (basal ganglia, thalamus, brain stem) 135 (19%) 
Cerebellar vermis 128 (18%) 
Chiasmatic-hypothalamic 28 (4%) 
  
Tumor histology  
Juvenile pilocytic astrocytoma 396 (76%) 
Fibrillary astrocytoma 43 (8%) 
Ganglioglioma 32 (6%) 
Oligodendroglioma 28 (5%) 
Pleomorphic xanthoastroctyoma 8 (1.5%) 
Other gliomas 7 (1.3%) 
Mixed gliomas 6 (1.2%) 
* Tumor location and histology in 713 children enrolled on CCG 9891/ POG 9130 low grade glioma 
study (adapted from Wisoff, J. H., J. M. Boyett, et al. (1998) 
Table 3. Distribution of low-grade gliomas in children based on location and histology 
2.1 The blood-brain barrier 
The BBB is composed of endothelium that covers almost the entire capillary network 
supplying the brain. The endothelium in the BBB is non-fenestrated with high-resistance 
tight junctions. Other components of the BBB include the astroglial processes, basement 
membrane, and pericytes (Gururangan and Friedman 2002) (Gururangan and Friedman 
2004). The foot processes of the astrocytes cover the entire capillary endothelium and are 
essentially interposed between the endothelium and the neurons (Gururangan and 
Friedman 2004). There is minimal pinocytotic activity across the endothelial cells. Hence, 
in a physiologic state, the BBB functions as a diffusion barrier preventing hydrophilic 
molecules less than 180 kilo Daltons from passively entering the brain, and is intended to 
keep noxious substances from damaging the neuronal cells (Englehard and Groothuis 
1999). The BBB serves to transport nutrients and water soluble substances between the 
blood and the CNS (Engelhard 2000). It also serves as a conduit for carrier mediated, 
energy-dependent specialized transport systems that enable specific molecules in the 
blood to cross the endothelium into the neurons (e.g., the glucose transporter, GLUT-1) or 
from the cell back to blood (e.g., p-glycoprotein efflux pump) (Englehard and Groothuis 
1999). The endothelium is fenestrated and permits free exchange of large molecules in 
some areas of the brain including pituitary and pineal glands, the median eminence, area 
postrema, subfornicial organ, and the lamina terminalis. The absence of the BBB is 
reflected by the appearance of normal contrast enhancement in these areas in 
neuroimaging studies. 
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2.1.1 Brain tumors cause disruption of the blood-brain barrier 
The proliferation and invasion of tumor cells in the brain generally results in the 
disruption of the brain microvasculature, breach of the BBB, and development of 
vasogenic edema even in small tumors (Gururangan and Friedman 2002). The BBB is 
histologically abnormal in the presence of a tumor with thickened basement membrane, 
increased pinocytotic activity within the endothelial cells, and diminished interaction 
between the pericytes and astrocytic foot processes causing increased fenestrations 
between endothelial cells and exudation of plasma into the tumor. This interstitial edema 
can in turn influence cerebral blood flow, brain metabolism, and intracranial pressure. 
Tumor cells also secrete pro-angiogenic factors including basic fibroblast growth factor 
(b-FGF) and vascular endothelial growth factor (VEGF) resulting in the influx of new 
blood vessels into the tumor, a process called tumor angiogenesis (Folkman 2007). These 
tumor capillaries are different from the capillaries of the normal brain in that they are 
hyperplastic, have frequent fenestrations, lax intercellular junctions, and less well 
developed glial processes abutting on the abluminal surface of the endothelium 
(Groothuis 2000). Thus the continuing proliferation of the tumor cells in the brain 
actually results in disruption of the BBB (Stewart 1994). However, it is possible that such 
disruption can be variable between tumors and even within a given tumor. Also, it is 
likely that small tumors (for e.g., the infiltrative edge of a malignant glioma) might have 
a relatively intact BBB that might lead to chemotherapy failure (Stewart 1994). 
2.1.2 Blood-brain barrier and efficacy of brain tumor chemotherapy 
In the ongoing search for more effective chemotherapeutic agents for patients with brain 
tumors, there is a general bias towards choosing lipophilic agents with a high octanol-water 
partition coefficient (a measure of the lipid solubility of the drug) to enable rapid transfer of 
these drugs from the blood to the tumor cells despite an intact BBB (Englehard and 
Groothuis 1999). However, as indicated in the previous section, it appears that the BBB 
might be disrupted even in small tumors allowing drug entry. Also, studies have shown 
that the average concentration of chemotherapeutic agents in brain tumors does not 
significantly differ from their extra cranial counterparts, although the homogeneity of drug 
distribution varies both within and between brain tumor deposits (Stewart 1994; 
Gururangan and Friedman 2002). Also, it must be remembered that while lipophilic drugs 
do penetrate the blood-brain barrier better, it does not necessarily translate into equal 
efficacy in all patients with brain tumors (Stewart 1994). There are clearly other reasons for 
chemotherapy failure in such patients besides the BBB (Groothuis 2000; Gururangan and 
Friedman 2002). Nevertheless, it is possible that disruption of the BBB may not be uniform 
in brain tumors and areas of the brain surrounding the main tumor may have a relatively 
intact BBB. This notion has led to an increasing trend towards devising methods that further 
disrupt the blood-tumor barrier to facilitate entry of chemotherapy into brain tumors. Such 
increased disruption could potentially increase drug concentration in areas where the 
barrier has not been completely disrupted by the tumor (Stewart 1994) and help 
chemotherapy reach areas of adjacent tumor infiltration wherein the barrier may be 
relatively intact (Stewart 1994; Englehard and Groothuis 1999). Alternatively, the BBB can be 
by-passed using strategies like intra-arterial or intra-thecal delivery of chemotherapeutic 
agents;  convection-enhanced delivery of large molecules like toxins directly into the tumor; 
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or intracavitary administration of chemotherapy wafers (e.g., Gliadel wafers, Eisai 
Pharmaceuticals, Woodcliff Lake, NJ) (Gururangan and Friedman 2002). 
3. Angiogenesis and brain tumors 
In 1971, Dr. Judah Folkman proposed that continued tumor growth after the initial tumor 
take (up to a 2 mm3 size) is dependent on growth of new blood vessels into the tumor 
(Folkman 2007). This influx of new capillaries was termed ‘tumor angiogenesis’. This initial 
hypothesis has since been confirmed in several studies and has led to the discovery of 
several pro angiogenesis and anti-angiogenesis factors (Folkman 2007). The principal pro-
angiogenesis mediators are α and β fibroblast growth factors (b-FGF), vascular endothelial 
growth factor (VEGF), angiogenin, and other factors (Folkman 2007). The principal negative 
regulators of new capillary growth are endostatin, thrombospondin-1 and 2, and angiostatin 
(Folkman 2007). While tumor dormancy is generally dependent on a balance between 
positive and negative regulators of angiogenesis, an excess of stimulators results in the 
“angiogenic switch” and exponential tumor growth (Hanahan and Folkman 1996). These 
pro-angiogenic factors can be produced by the tumor cells, mobilized from the extracellular 
matrix through matrix metalloproteases (MMP), or released by macrophages or neutrophils 
attracted to the tumor through elaboration of VEGF (Folkman 2007). The angiogenic process 
also leads to tumor invasion and ultimately metastasis to other body sites (Folkman 2007). 
This induction of angiogenesis is the reason why neovascularization is present in most brain 
tumors (Li, Folkerth et al. 1994).  Immunohistochemical studies have demonstrated the 
presence of angiogenic factors including b-FGF in high concentrations in brain tumors (Li, 
Folkerth et al. 1994). This peptide stimulates vascular endothelial cell proliferation and such 
cells either produce or possess receptors for b-FGF. Li et al. have detected b-FGF in the 
cerebrospinal fluid (CSF) in 62% of children with brain tumors but none in controls (Li, 
Folkerth et al. 1994). The CSF specimens with elevated b-FGF increased the DNA synthesis 
of capillary endothelial cells in vitro and such activity was blocked by neutralizing antibody 
to b-FGF. The concentration of b-FGF in CSF was also correlated with increased micro vessel 
density (MVD) in histologic sections of the brain tumors and negatively correlated with 
prognosis. While b-FGF was the only proangiogenic factor studied in this report, it is 
possible that other angiogenic peptides could mediate growth of brain tumors including 
VEGF, integrins (ǂvǃ3, ǂvǃ5,
 
ǂ3ǃ1), Platelet derived growth factor (PDGF), plasminogen 
activator, cyclooxygenases, and copper. VEGF is highly expressed in several types of 
primary brain tumors (Leung, Chan et al. 1997; Huang, Held-Feindt et al. 2005) and is an 
important growth factor that sustains endothelial proliferation, survival, and motility 
(Kerbel 2008). There are four cognate VEGF receptors including VEGFR-1 (flt-1), VEGFR-2 
(KDR), VEGFR-3, and VEGFR-4. However, VEGFR-2 is the most important receptor that 
mediates the effects of VEGF on the endothelial cells (Kerbel 2008). The level of VEGF 
expression has also been correlated with outcome in patients with glioblastoma multiforme 
(Kim, Li et al. 1993). 
The demonstration of the role of angiogenesis in sustaining tumor growth has led to the 
exploration of inhibitors of angiogenesis as a means of curtailing tumor progression. Elegant 
pre-clinical studies in mouse tumor xenograft models have shown dramatic tumor 
regression and cure of animals bearing tumors (Boehm, Folkman et al. 1997). There are at 
least 40 such inhibitors in various stages of clinical development in a wide variety of tumors 
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in centers in the U.S and Europe, and should help our understanding of the toxicity, dose 
schedules, and possibly the usefulness of these agents in these malignancies.(Folkman 2007). 
Three of these agents have received FDA approval, including Bevacizumab (Avastin™, 
Genentech Corporation, San Francisco, USA) (for colorectal cancer, lung cancer, 
glioblastoma mulitforme), Sorafenib (Nexavar™, Bayer Pharmaceuticals, Berlin, 
Germany)(for renal carcinoma), and Sunitinib (Sutent™, Pfizer Corporation, USA) (for renal 
carcinoma) (Folkman 2007). In particular, Bevacizumab (a humanized antibody against 
VEGF), AZD2171 (Cediranib, Astra Zeneca, U.K.) (VEGF-R2 inhibitor), and Cilengitide (an 
integrin ǂvǃ3, ǂvǃ5 inhibitor) (EMD121974; Merck KGaA, Darmstadt, Germany) have 
undergone extensive evaluation in adults with malignant glioma and are currently being 
tested in phase III trials against standard therapy (Reardon, Desjardins et al. 2008). 
4. Advances in the treatment of pediatric brain tumors 
4.1 Low-grade gliomas 
Pediatric low-grade gliomas (LGG) are a heterogeneous group of tumors and constitute 
the most frequent CNS neoplasia encountered in children (30-40% of all CNS tumors 
diagnosed in the United States) (Watson, Kadota et al. 2001). They can be classified based 
on histology or location (Table 3). Pilocytic astrocytoma is the commonest LGG in 
children with an incidence of 0.79 per 100,000 person-years. The commonest neuro-
cutaneous syndrome associated with LGG is Neurofibromatosis Type I (NF-1). The 
genetic mutation is NF-1 is located on chromosome 17q and results in loss of the GTP-ase 
activating protein (GAP), Neurofibromin. Lack of Neurofibromin activity results in 
increased activity of the RAS- MAPK, cyclic AMP, and mTOR signaling pathways, and 
cellular proliferation (Rubin and Gutmann 2005). About 15% of patients with NF-1 
develop LGG (typically piloyctic astrocytoma, WHO grade I) and less commonly, other 
gliomas (Reed and Gutmann 2001). NF-1 patients with LGG have a more favorable 
prognosis than those with sporadic tumors (Gururangan, Cavazos et al. 2002). The risk 
factors for development of non-NF-1 LGG is largely unknown although one case-control 
study identified an increased risk of developing  low grade brain stem gliomas in the 
offspring of mothers who ingested an excessive amount of cured meats during pregnancy 
(Preston-Martin, Pogoda et al. 1996). 
The pathology of pilocytic astrocytoma is one of low cellularity and a biphasic pattern of 
solid sheets of bipolar cells and Rosenthal fibers along with areas of micro and macro cysts 
(Burger, Scheithauer et al. 2000). The tumor nuclei typically lack anaplasia. The tumor 
demonstrates hyalinized glomerular blood vessels that are quite leaky and hence cause 
intense contrast enhancement on neuroimaging studies. The pilomyxoid astrocytoma is a 
closely related tumor type that occurs predominantly in the hypothalamic/chiasmatic 
region and is characterized by the presence of a myxoid matrix and angiocentric 
arrangement of monomorphous bipolar cells, and has a high predilection for 
leptomeningeal spread (Louis, Ohgaki et al. 2007).  
4.2 Treatment 
Since these tumors only rarely metastasize through the neuraxis, local control using surgery 
and/or radiotherapy have been the traditional components of therapy for patients with LGG. 
Due to a direct positive correlation between extent of resection and progression-free and 
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overall survival (PFS and OS), aggressive surgery of tumor should be attempted in tumor 
locations where feasible (Watson, Kadota et al. 2001). The cystic cerebellar astrocytoma is an 
example of a LGG that can be resected completely without causing neurologic deficits and 
results in cure rates of over 90% (Figure 2) (Watson, Kadota et al. 2001). Similarly, exophytic 
tumors of the brain stem including the cervico-medullary region are typically pilocytic 
astrocytomas, amenable to complete surgical removal, and have an excellent prognosis 
(Watson, Kadota et al. 2001). Tectal plate gliomas usually present with hydrocephalus due to 
early compression of the cerebral aqueduct. Patients with these tumors are observed without 
any treatment after controlling hydrocephalus with a third ventriculostomy. The operating 
microscope and ultrasonic surgical aspirator allows the surgeon to perform an adequate tumor 
resection without compromising adjacent normal brain. Pre-operative imaging can be 
correlated with intra-operative observation using frame-based or frameless stereotactic system 
that also help in guiding the surgeon with trajectories to deep-seated lesions. Functional 
magnetic resonance imaging, positron emission tomography, and electrode grids for mapping 
areas of the cerebral cortex have helped the surgeon to accurately delineate tumor margins and 
improve post -surgical morbidity in these patients. However, tumors in certain areas of the 
brain (about 30% of all LGG) are still unsafe for surgical resection and include the optic 
pathway, diencephalon (hypothalamus and thalamus), and intrinsic portion of the brain stem. 
For tumors in such locations and those that recur after initial surgical resection and/or cause 
functional impairment, chemotherapy and/or radiotherapy (RT) can be used for disease 
control. There are no reported prospective randomized trials assessing the benefits of adjuvant 
radiotherapy in children with LGG (Watson, Kadota et al. 2001). Extrapolating data from adult 
phase III trials, it seems appropriate to use focal radiotherapy in doses of 45-54 Gy in 1.8 to 2.0 
Gy fractions. Three-D conformal RT, intensity modulated RT, and proton-beam therapy are 
new radiation delivery techniques that are designed to minimize damage to normal brain but 
await validation in larger studies (Watson, Kadota et al. 2001). A preliminary report from St. 
Jude Children’s Hospital explored the usefulness of 3-D conformal RT in patients with 
localized LGG (Merchant, Happersett et al. 1999). Thirty eight patients (median age 8.7 years, 
range 2.2 -18.7) with LGG (JPA, 25) were enrolled on this phase II trial. With a median follow-
up of 17 months (range, 3-44), four patients have suffered local failures, 3 within the clinical 
target volume (CTV) and one just outside the CTV. While data from this study is encouraging 
for limited field radiotherapy, long-term follow up is required to assess the impact of field 
reduction on long-term complications and outcome. In view of the deleterious effect of 
radiotherapy on the growing brain in young children, chemotherapy agents including 
vincristine, actinomycin-D, cyclophosphamide, carboplatin, lomustine, and etoposide have 
been employed individually or in combination in patients with progressive LGG to delay or 
avoid irradiation (Gururangan, Cavazos et al. 2002). Following preliminary clinical evidence of 
activity, carboplatin, a second-generation cisplatin analog, either alone or in combination with 
vincristine, has been used as a frontline therapy for children with low-grade glioma, 
particularly for those with optic pathway tumors (Friedman, Krischer et al. 1992; Packer, Ater 
et al. 1997; Gururangan, Cavazos et al. 2002). Objective responses and disease stabilization 
have been observed in 25-58% and 80-90% of patients respectively in these studies. The three-
year PFS in patients with recurrent low-grade glioma following this chemotherapy regimen 
has been reported to be 64-68% (Packer, Ater et al. 1997; Gururangan, Cavazos et al. 2002).  
Myelosuppression is the main toxicity related to carboplatin followed by allergic reactions in 
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about 10-30% of patients (Gururangan, Cavazos et al. 2002). An alternative nitrosourea – based 
chemotherapy regimen [6-Thioguanine, Procarbazine, Lomustine (CCNU), Vincristine, and 
Dibromodulcitol] was reported by Prados et al., and was shown to produce prolonged disease 
stabilization in children with progressive LGG (Prados, Edwards et al. 1997). This treatment 
combination without Dibromodulcitol (TPCV regimen) was evaluated in comparison with the 
carboplatin + vincristine combination in a Children’s Oncology Group phase III trial in 401 
eligible children with progressive or symptomatic LGG (Ater, Holmes et al. 2008). The results 
of this study, available in abstract form, showed that both regimens were efficacious in 
prolonging disease-free survival (median time to progression of 3.2 and 4.9 years for 
carboplatin + vincristine and TPCV regimens respectively) and enabled delaying 
radiotherapy. The overall survival was 86% for non- NF-1 children and 98% for those with NF-
1 (p= 0.0017), again demonstrating that NF-1 patients with recurrent LGG have a better 
prognosis than those without NF-1. Recently, we and others have also reported on the efficacy 
of Temozolomide (an oral methylating imadazole tetrazinone compound) in both adults and 
children with LGG (Kuo, Weiner et al. 2003; Quinn, Reardon et al. 2003; Gururangan, Fisher et 
al. 2007). In a phase II trial of 26 children with progressive/recurrent optic pathway or juvenile 
pilocytic astrocytoma, the disease stabilization rate was over 50% for a median interval of 34 
months (Gururangan, Fisher et al. 2007).  
4.3 Molecular alterations in pediatric LGG and novel therapies 
While Nf-1 loss is clearly related to the genesis of tumors in patients with NF-1, the 
molecular events in sporadic LGG had not been well characterized until recently. Several 
groups have now identified tandem duplication of 7q34 that contains the BRAF gene in 
about 60-80% of sporadic pilocytic astrocytomas resulting in a fusion product between 
KIAAI549 and BRAF that includes the BRAF kinase domain without the auto-inhibitory N-
terminus (Pfister, Janzarik et al. 2008; Yu, Deshmukh et al. 2009). This is an activating 
mutation that is also present in 50% of fibrillary astrocytomas. On the other hand, an 
activating point mutation in Exon 15 position 600 of the BRAF gene (BRAF V600E) is 
found in over 40% of gangliogliomas but only rarely in pilocytic astrocytomas 
(Dougherty, Santi et al. 2010). BRAF is a member of the RAF family of serine-threonine 
protein kinases and is a key intermediary in the RAS-RAF-MEK-ERK- MAP kinase 
pathway(Yu, Deshmukh et al. 2009). Activation of BRAF would signal downstream via 
MEK-ERK and finally MAP-kinase resulting in cellular proliferation. In fact, tumors with 
activating mutations of BRAF were found to have overexpression of MAP-K (Kolb, 
Gorlick et al. 2010).  
In contrast to sporadic tumors, BRAF mutations are not found in NF-1 associated pilocytic 
astrocytomas (Yu, Deshmukh et al. 2009). It is therefore possible that this mutation is an 
initiating event only in non- NF-1 tumors. Interestingly,  this activating mutation seems to 
be preferentially expressed in posterior fossa tumors (Yu, Deshmukh et al. 2009). In addition 
to BRAF mutations, HIPK2 (Homeo-box interfering protein kinase 2) amplifications have 
been identified in a proportion of sporadic pilocytic astrocytomas that also harbor BRAF 
rearrangements (Yu, Deshmukh et al. 2009). The significance of this molecular event is 
unknown. In addition, VEGF overexpression has also been observed in pilocytic 
astrocytomas and might explain the intense vascular proliferation seen in these tumors 
(Leung, Chan et al. 1997).  
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Fig. 2. T-1 weighted axial and sagittal gadolinium enhanced images of the brain in a 4-year 
old male demonstrating an enhancing cystic lesion in the cerebellum that is compressing the 
IV ventricle and causing hydrocephalus. Histology of this mass was a pilocytic astrocytoma. 
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Biologic therapies are being increasingly used in children with recurrent LGG using 
information on expression of specific targets in these tumors. The intense vascularity of 
pilocytic astrocytoma implies that these tumors might be susceptible to anti-angiogenic 
therapies. Using the principle of metronomic chemotherapy that preferentially kills tumor 
endothelial cells rather than tumor (Kerbel, Viloria-Petit et al. 2000), Bouffet et al., conducted 
a phase II study of intravenous vinblastine 6 mg/m2/week administered for up to 52 weeks 
in 51 patients with recurrent LGG (Bouffet, Jakacki et al. 2008). Disease stabilization was 
obtained in 42% of patients at a median follow up of 31 months from starting treatment. In a 
recent phase I study of Lenalidomide (an immune modulating drug and angiogenesis 
inhibitor) in children with recurrent brain tumors, Warren et al., reported objective 
responses in 2 patients with an optic pathway glioma and pilocytic astrocytoma respectively 
(Warren, Goldman et al. 2011). Similarly, Packer et al., have observed sustained objective 
responses or disease stabilization and improvement in neurologic deficits in 7 of 9 children 
with multiply recurrent LGG treated with Bevacizumab plus irinotecan (Camptosar™, 
Pfizer corporation, USA) (Packer, Jakacki et al. 2009). A multi-institutional phase II trial of 
the same combination in children with recurrent LGG has just been completed and results of 
this study should be available soon. 
Since about 70% of sporadic pilocytic astrocytomas express activating BRAF mutations, 
there has been an interest in using targeted inhibitors of the BRAF pathway. In the 
pediatric pre-clinical testing program (PPTP), AZD6244, a potent and selective inhibitor of 
MEK1/2 kinases, demonstrated significant activity in one of two JPA xenografts that 
carried the activating V600E mutation (Kolb, Gorlick et al. 2010). There is an ongoing 
multi-institutional phase I trial in the United States through the National Cancer Institute 
sponsored Pediatric Brain Tumor Consortium (PBTC) using AZD6244 in older children 
with recurrent low-grade gliomas testing the toxicity, pharmacokinetics, and preliminary 
assessment of efficacy of this agent in this population (Larry Kun M.D., Memphis, TN; 
personal communication 2011).  
5. Primitive neuroectodermal tumors  
Primitive neuroectodermal tumors (PNET) of the central nervous system (CNS) are a group 
of aggressive embryonal neoplasia that occurs both in adults and children. Under this broad 
rubric, three tumors are mainly recognized based on their location - medulloblastoma, 
which occurs exclusively in the cerebellum, pineoblastoma in the pineal gland, and 
supratentorial PNET in the cerebral hemispheres or suprasellar region. Although 
histologically similar with a propensity for aggressive neuraxis dissemination, these tumors 
markedly differ in terms of genetic makeup and prognosis. In recent years, much 
controversy has been generated in the histologic classification of PNET (Rorke 1983). 
Simultaneously, considerable progress has been made in identifying the molecular 
characteristics of these tumors, particularly medulloblastoma (Pomeroy, Tamayo et al. 2002 ; 
Gilbertson 2004). Also, significant strides have been made in the treatment of patients with 
these malignancies.  
5.1 Medulloblastoma 
Medulloblastoma is the most common malignant brain tumor in children. About 400 
children are diagnosed with this tumor each year in the United States (Gurney, Smith et al. 
1999). The peak age of onset is between 5-9 years of age. Over 90% of medulloblastoma 
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typically arise from the superior medullary velum, grows and fills the cavity of the fourth 
ventricle (Figure 3a) (Mclendon, Enterline et al. 1998). The tumor mass can encroach on to  
 
 
 
 
Fig. 3. a: Figure: T-1 weighted axial and sagittal gadolinium enhanced images of the brain in 
a 16-year old black female that demonstrates a heterogeneously enhancing mass filling the 
IV ventricle and causing obstructive hydrocephalus 
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the cisterna magna and sometimes infiltrates the floor of the fourth ventricle or brain stem. 
A minority of tumors, particularly in patients over 16 years of age, arises more laterally in 
the cerebellar hemispheres (Mclendon, Enterline et al. 1998). Macroscopically, these tumors 
are soft, friable, and moderately demarcated from the cerebellar tissue. Areas of central 
necrosis may be present. The microscopic structure of medulloblastoma is characterized by 
densely packed cells with round to oval carrot –shaped highly hyperchromatic nuclei 
surrounded by scanty cytoplasm. Neuroblastic rosettes are a typical but not constant 
feature. The main pathologic subtypes of medulloblastoma recognized in the 2000 World 
Health Organization (WHO) classification of brain tumors include classic, desmoplastic, 
extensive nodularity with advanced neuronal differentiation, and the large cell/anaplastic 
varieties (Giangaspero, Perilongo et al. 1999; Giangaspero, Bigner et al. 2000; Leonard, Cai et 
al. 2001; Louis, Ohgaki et al. 2007). The predominant presenting symptoms in patients with 
this tumor are those of raised intracranial pressure including irritability, headache, lethargy, 
vomiting, and poor school performance (Packer, Cogen et al. 1999). Additional symptoms 
due to invasion of other local structures include truncal ataxia, nystagmus, neck stiffness, 
and cranial nerve palsies. Dissemination of tumor to the leptomeninges  (Figure 3b) occurs 
in about 10-30% of cases, with infants suffering this complication more frequently than older 
children. In less than 10% of cases, the tumor can spread outside of the neuraxis (Packer, 
Cogen et al. 1999). Patients with certain genetic disorders including Gorlin’s (nevoid-basal 
cell carcinoma syndrome), p-53 germline mutation, and Turcot’s syndromes have a higher 
risk of developing medulloblastoma (Packer, Cogen et al. 1999).  
 
 
Fig. 3. b: T-1 weighted sagittal gadolinium enhanced image of the spine in a 2-year old black 
female with posterior fossa medulloblastoma demonstrating multiple nodular metastatic 
lesions along the spinal cord 
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5.2 Treatment 
Patients with medulloblastoma are classified as average or high-risk to enable assignment 
of appropriate treatment based on the extent of tumor following surgery. Those with 
average risk disease are over > 3 years of age and have ≤ 1.5 cm2 of tumor in the primary 
site and no brain stem involvement or metastatic disease (Packer, Cogen et al. 1999). 
Patients with high-risk medulloblastoma include children < 3 years at the time of 
diagnosis, and those who have gross residual disease post-surgery or metastatic disease 
(Packer, Cogen et al. 1999). Conventional therapy for patients with low-risk 
medulloblastoma is complete surgical resection followed by craniospinal irradiation (24-
36 Gy) and a focal boost to the primary site (54 - 56 Gy) with a 5-year event-free survival 
rate of approximately 60% (Packer, Cogen et al. 1999; Freeman, Taylor et al. 2002). The 
addition of chemotherapy (vincristine, cisplatin, and lomustine or cyclophosphamide) 
appears to benefit patients with high-risk features and might help to decrease the dose of 
neuraxis irradiation in patients with average risk disease (Packer, Cogen et al. 1999; 
Freeman, Taylor et al. 2002). Infants with medulloblastoma fare poorly with standard 
chemotherapy and irradiation and have a higher incidence of neuro-cognitive deficits 
following radiotherapy (Duffner, Horowitz et al. 1993; Walter, Mulhern et al. 1999). There 
is evidence that some infants can be successfully treated with high-dose chemotherapy 
alone without neuraxis irradiation (Mason, Grovas et al. 1998). 3-D conformal 
radiotherapy is currently being utilized in children with medulloblastoma in an attempt 
to delivery radiation boost to the tumor bed and residual tumor and decrease radiation 
scatter to the cochlea, supratentorial brain, and hypothalamus. Preliminary results from 
single- institution studies appear promising with no increased failures documented in the 
posterior fossa (Merchant, Happersett et al. 1999; Wolden, Dunkel et al. 2003) and lesser 
risk of oto-toxicity and neuro-cognitive deficits. The validity of these results will be 
further tested in a randomized fashion in the ongoing Children’s Oncology Group (COG) 
phase III trial (ACNS 0331) for average- risk medulloblastoma in children. 
Patients with recurrent tumors fare very poorly despite conventional retrieval therapy 
with few or no long-term survivors. The use of high-dose chemotherapy (HDC) with stem 
cell rescue has been useful in prolonging PFS in a proportion of patients with tumors that 
are localized and sensitive to standard chemotherapy, relapse following chemotherapy 
only, and hence can also receive standard doses of radiotherapy in addition to HDC 
(Dunkel, Boyett et al. 1998; Guruangan, Dunkel et al. 1998; Gururangan, Krauser et al. 
2008). In contrast, studies at Duke University Medical Center and others have shown that 
this strategy does not seem to be efficacious in those patients who relapse after receiving 
standard chemotherapy and radiotherapy (Gururangan, Krauser et al. 2008). Recurrent 
medulloblastoma is invariably associated with leptomeningeal dissemination (LMD) at 
some point in its disease course. Treatment for LMD with currently available options is 
suboptimal. Intrathecal chemotherapy with thiotepa, mafosfamide, or busulfan has been 
tested in phase I/II clinical trials in patients with LMD (Gururangan and Friedman 2002). 
However, benefits are transient since the delivered chemotherapy is unable to penetrate 
beyond a few millimeters into the tumor tissue from CSF due to the high interstitial 
pressure within the tumor. More innovative therapies are needed to improve outcome for 
patients with recurrent medulloblastoma through a better understanding of the biology of 
the tumor. 
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5.3 Molecular characteristics and biologic therapy 
There has been a profusion of studies describing the molecular characteristics of 
medulloblastoma including the Sonic-Hedgehog and WNT signaling pathways, Trk-C 
expression, c-Myc amplification, OTX-2 amplification, presence of isochromosome 17q, 
erBB-2 and 4 over-expression, and PDGFR ǂ and RAS/MAP-kinase activation, that can 
predict the biologic behavior and outcome independent of clinical characteristics (Packer, 
Cogen et al. 1999; MacDonald, Brown et al. 2001; Gilbertson 2004; Di, Liao et al. 2005).  At 
least one clinical trial has prospectively validated the usefulness of some of these molecular 
markers and, in future, could potentially help to decrease therapy for those patients with 
favorable biologic features (Gajjar, Chintagumpala et al. 2006).  Whereas patients with WNT 
pathway activation identified by beta-catenin point mutations on residue S33 and S37 have a 
100% survival with standard risk adapted therapy, those with either SHH or non-SHH/non-
WNT tumors have an inferior survival (Gajjar, Chintagumpala et al. 2006; Schwalbe, 
Lindsey et al. 2011). More recently, gene expression profiling of medulloblastoma has 
revealed that tumors cluster within four distinct molecular groups; WNT, SHH, Group C, 
and D (Northcott, Korshunov et al. 2010). Interestingly, each group could be identified by 
immunohistochemistry or mRNA based expression potentially allowing for easy 
categorization of prospective patients at diagnosis (Northcott, Korshunov et al. 2010; 
Schwalbe, Lindsey et al. 2011). Such classification has potential advantages of allowing for 
stratification of intensity of standard therapy based on the known prognosis of each group 
and possibly using specific small molecule kinase inhibitors specific for that group. An 
activating mutation of the Smoothened gene is present in about 10% of sporadic 
medulloblastoma and tumors harboring this mutation would be responsive to Smoothened 
inhibitors. GDC 0449 (Genentech Corporation, San Francisco, USA) is one such inhibitor that 
has shown excellent activity in transgenic PATCH mouse models of medulloblastoma 
(Romer, Kimura et al. 2004) and in one patient with metastatic medulloblastoma (Rudin, 
Hann et al. 2009). Recently, retinoids including All Trans Retinoic Acid (ATRA) and 13-cis 
retinoic acid have been found to mediate apoptosis in medulloblastoma cells and decrease 
tumor growth in xenograft mouse models, especially those bearing anaplastic 
medulloblastoma with OTX-2 amplification (Hallahan, Pritchard et al. 2003) (Di, Liao et al. 
2005). On this basis, an ongoing COG trial will test the efficacy of 13 cis-retinoic acid in a 
randomized fashion along with maintenance chemotherapy in children with high-risk 
medulloblastoma. A recent pre-clinical study demonstrated that while 9-cis retinoic acid 
reduced growth of an OTX-2 overexpressing D425 medulloblastoma xenograft implanted in 
the flanks of athymic mice but failed to do so in intracranial implants of the same tumor 
(Bai, Siu et al. 2010). Fibroblast growth factor (FGF) expression was implicated in the failure 
of retinoic acid therapy in the intracranial tumor model and resistance can be abrogated by 
combining 9- cis retinoic acid with a specific FGF inhibitor (Bai, Siu et al. 2010). 
5.4 Pineoblastoma and other supratentorial PNET 
The incidence of pineoblastoma is approximately 3-10% of all primary malignant brain 
tumors in all age groups (Jakacki 1999) They constitute approximately 45% of all pineal 
parenchymal tumors. They usually occur in the first 2 decades of life with most cases 
occurring in the within 10 years. A familial tendency for occurrence of PNET in pineal or 
suprasellar region has been observed in patients with familial retinoblastoma, also called the 
trilateral retinoblastoma syndrome (Paulino 1999; Singh, Shields et al. 1999). Other 
supratentorial PNETs including cerebral neuroblastoma, ependymoblastoma, and 
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medulloepithelioma constitute 1-2% of all CNS tumors and about 6% of all CNS PNETs. 
These tumors occur commonly in the cerebral hemispheres, periventricular region, 
thalamus, hypothalamus, basal ganglia, and rarely as diffuse leptomeningeal disease 
without a evidence of a primary tumor (Jennings, Slatkin et al. 1993; Dai, Backstrom et al. 
2003). These tumors mostly occur in young children with a median age at diagnosis of 5.5 
years (range, 4 weeks to 10 years) and a male predominance (Jakacki 1999). Supratentorial 
PNETs have been known to occur following cranial irradiation as a second malignancy 
(Hader, Drovini-Zis et al. 2003). No specific genetic associations have been noted in patients 
with these tumors. The histologic features of these tumors are similar to that of 
medulloblastoma.  
The clinical features of pineoblastoma include those due to hydrocephalus due early 
compression of the aqueduct and pressure on the tectum of the mid-brain which produces 
the Parinaud’s syndrome. Cerebral PNETs typically cause headache, vomiting, and seizures 
depending upon the location of the tumor (Berger, Edwards et al. 1983; Dai, Backstrom et al. 
2003). 
5.4.1 Treatment 
The treatment of these tumors includes surgical resection, chemotherapy, and radiotherapy 
(Jakacki 1999; Gururangan, McLaughlin et al. 2003). However, survival for patients with 
these tumors is far inferior compared to those with medulloblastoma. Infants with 
supratentorial PNET have a dismal prognosis with standard chemotherapy and irradiation 
(Duffner, Horowitz et al. 1993; Jakacki 1999). In contrast, a PFS of over 60% has been 
observed in older children with pineoblastoma treated with lomustine (CCNU), vincristine, 
and prednisone or the “8 in 1” drug regimen following neuraxis irradiation and a focal 
boost to the pineal region (Jakacki 1999). The use of HDC with stem cell rescue plus 
radiotherapy has also resulted in improved survival in some children with these tumors 
especially for those with metastatic disease (Mason, Grovas et al. 1998; Gururangan, 
McLaughlin et al. 2003; Gururangan, Driscoll et al. 2008; Chintagumpala, Hassall et al. 2009). 
The efficacy of HDC in infants with pineoblastoma has been encouraging even without the 
need for radiotherapy (Gururangan, McLaughlin et al. 2003). Optimal management of 
children with pineoblastoma and other supra-tentorial PNETs continues to be a challenge 
and further therapeutic refinements are needed especially for those with recurrent disease.  
5.4.2 Molecular characteristics  
Although supratentorial PNETs resemble medulloblastoma histologically, the inferior 
survival seen in this group despite using intensive therapies as used for metastatic 
medulloblastoma suggest that there are intrinsic biologic differences between these two 
tumors. The most common non-random chromosomal abnormality is 4q loss occurring in 
50% of cases (Li, Bouffet et al. 2005). In contrast to medulloblastoma, none of the 
supratentorial PNETs expresses isochromosome 17q. Other molecular characteristics include 
high NOTCH2 expression, and p53 dysfunction (as indicated by p53 immunopositivity) (Li, 
Bouffet et al. 2005). In addition, heritable loss of the mismatch repair gene PMS2 
(homozygous missense mutation in exon 14) results in learning difficulties, café-au-lait 
spots, and early onset of supratentorial PNETs has been described in two siblings of a 
heavily consanguineous family (De Vos, Hayward et al. 2006). It appears that supratentorial 
PNETs might arise due to impaired DNA repair mechanisms as evidenced by the presence 
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of high p53 immunopositivity, occurrence following exposure to radiotherapy, and in the 
context of mismatch repair mutations (Li, Bouffet et al. 2005). 
6. High-grade glioma 
High-grade glioma (HGG) including anaplastic astrocytoma (AA, WHO grade III) and 
glioblastoma multiforme (GBM, WHO Grade IV) constitutes about 14% of CNS tumors in 
children. These tumors can occur anywhere in the brain. In a recent Children’s Cancer 
Group study report of 131 evaluable children with HGG, over 90% of tumors occurred in a 
supratentorial location (63% in the superficial cerebral hemisphere (Figure 4a and 4b) and 
38% in the deep or midline cerebrum and only 8% occurred in the posterior fossa (including 
brain stem and cerebellum) (Wisoff, Boyett et al. 1998). The principal histologic features of 
AA are increased cellularity, nuclear atypia, and marked mitotic activity. The neoplastic 
cells are consistently positive for glial fibrillary acidic protein and have a proliferative index 
of around 5-10%. GBM on the other hand is made up of pleomorphic astrocytic cells with 
brisk mitotic activity, nuclear atypia, vascular proliferation, and areas of necrosis. 
 
  
4a       4b 
Fig. 4. a and b: Axial T-1 weighted gadolinium enhanced and T-2 weighted images of the 
brain in a 13-year old boy who presented with seizures. Biopsy of the enhancing lesion 
revealed an anaplastic astrocytoma. Note the satellite lesion posterior to the main tumor 
mass and the extensive T-2 signal abnormality that extends beyond the enhancing lesion 
and indicates peritumoral edema and potentially non-enhancing tumor 
6.1 Treatment 
Treatment of HGG in any site includes adequate surgical resection, radiotherapy, and 
chemotherapy. The efficacy of this combined modality approach was recently demonstrated 
in a Children’s Cancer Group phase III randomized study (CCG-945) in which children with 
HGG received surgical resection followed by either vincristine, lomustine (CCNU), and 
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prednisone (control arm) or the “8 in 1” chemotherapy regimen (experimental arm) (Finlay, 
Boyett et al. 1995; Wisoff, Boyett et al. 1998). While there was no difference in 5-year PFS 
between the two arms of the study, the extent of surgical resection (> 90% vs. ≤ 90% 
resection) as assessed by post-operative imaging, was highly predictive of outcome with 
patients who had complete resection ( > 90%) having a significantly better 5-year PFS as 
compared to those with less extensive resection (≤ 90%) [AA + GBM, 35% vs. 17%, p = 0.006; 
AA, 44% vs. 22% and GBM, 29% vs. 4%]. Based on the favorable outcome and FDA approval 
of using Temozolomide (Temodar™, Schering Plough Corporation, Kenilworth, New 
Jersey) concurrently with radiotherapy in adults with newly diagnosed glioblastoma 
multiforme especially those with methylation of the MGMT promoter (Cohen, Johnson et al. 
2005), a pediatric phase II study was done in children with newly diagnosed malignant 
glioma in conjunction with radiotherapy followed by maintenance treatment for one year 
(Cohen, Pollack et al. 2011). The outcome for children with either Grade III or IV 
astrocytoma was no different compared to those who were treated on CCG-945 but over 
expression of MGMT was associated with poorer survival (Cohen, Pollack et al. 2011). 
Temozolomide does not provide the same benefit in children as it does for adults with HGG 
either at diagnosis or relapse (Gilbert, Friedman et al. 2002; Lashford, Thiesse et al. 2002). 
Other chemotherapeutic agents including irinotecan (CPT-11) have been utilized in children 
with HGG with only modest benefit (Turner, Gururangan et al. 2002). The combination of 
BCNU or Temozolomide with topoisomerase I inhibitors like CPT-11 has demonstrated 
synergism in pre-clinical studies (Gururangan and Friedman 2002). These combinations 
have been tested in adult clinical trials at our institution but with only modest benefits 
(Reardon, Quinn et al. 2004; Quinn, Jiang et al. 2009). Although mismatch repair defects in 
the tumor is a putative mechanism for resistance in tumors that do not respond to 
methylating agents like Temozolomide despite low AGAT expression, very few such tumors 
have been noted to harbor MMR deficiency (Pollack, Hamilton et al. 2010). Alternatively, 
excessive base excision repair (BER) could be operative in the face of overexpression of the 
enzyme poly (ADP-Ribose) polymerase (PARP) in these tumors. Inhibition of PARP prior to 
treatment with Temozolomide would prevent BER and make the tumor sensitive to the 
drug again. ABT -888 (Olaparib™, Abbot Laboratories, USA) is an effective PARP inhibitor 
that has been shown to effectively deplete PARP in tumors and is undergoing clinical testing 
both as a single agent and in combination with chemotherapy and other cytotoxics. 
Temozolomide + ABT-888 is currently being evaluated both in adults with malignant 
glioma and children with recurrent brain tumors.  
Children with midline HGG including those in the thalamus and diffuse intrinsic lesions 
within the brain stem (e.g., diffuse pontine glioma) are unresectable based on location and 
have a grave prognosis (Reardon, Gajjar et al. 1998; Mandell, Kadota et al. 1999). While 
patients with thalamic tumors undergo biopsy to confirm histology of HGG, it is no longer 
deemed necessary in patients with MRI findings of a diffuse intrinsic brain stem glioma. The 
use of radiotherapy and chemotherapy has had little impact on the dismal outcome of these 
patients in recent years (Mandell, Kadota et al. 1999; Cohen, Heideman et al. 2011).  
Since drug resistance and the blood-brain barrier are considered to be the most important 
impediments to effective chemotherapy in brain tumors, strategies have been devised to 
circumvent these barriers (Gururangan and Friedman 2002). For locally invasive tumors like 
HGG, therapies that circumvent the BBB include intra-cavitary implantation of BCNU 
wafers (Gliadel™ wafers, Aventis Corporation, USA), use of agents that disrupt the BBB, 
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intra-arterial chemotherapy with or without BBB disruption, and convection-enhanced 
delivery (CED) (Gururangan and Friedman 2002). A modest but significant efficacy was 
noted with the use of polymers impregnated with BCNU (Gliadel™ wafers, Aventis 
Corporation, USA) in a phase III randomized double-blind trial in adults with malignant 
glioma (Brem, Piantadosi et al. 1995; Westphal, Hilt et al. 2003). Intra-arterial chemotherapy 
using agents like carmustine, cisplatin, and etoposide, despite some theoretical advantages, 
has not proven to be useful but has some prohibitive neuro-toxicities (Gururangan and 
Friedman 2002). Transient disruption of the BBB can be achieved with chemical agents 
including mannitol, prostaglandin, histamine, and bradykinin that then facilitate 
chemotherapy entry into the brain tumor (Gururangan and Friedman 2002). Recently, 
Labridimil (Cereport™), a bradykinin analogue, has been used as a BBB disrupting agent 
prior to carboplatin chemotherapy (Warren, Patel et al. 2001). However, preliminary trials 
using this combination have had disappointing results. 
Convection-enhanced delivery is a recently described method of delivering large molecules 
via a micro infusion pump directly into the tumor using strategically placed catheters 
(Kunwar 2003; Sampson, Akabani et al. 2003). Using a pressure gradient, the solution 
containing the large molecules (typically a tumor toxin) penetrates directly through the 
tumor by convection and reaches several centimeters beyond the tumor (Gururangan and 
Friedman 2002). Toxins used have been fusion proteins made up of pseudomonas exotoxin 
and either Transforming growth factor or interleukin -13 (IL-13 PE38QQR)  (Kunwar, 
Prados et al. 2007). The latter molecules are designed to target the cognate receptors 
expressed selectively on glioma cells and spare normal brain tissue. Once the glioma cells 
are targeted, the exotoxin is internalized and causes cytotoxicity (Kunwar, Prados et al. 
2007) This strategy has undergone extensive testing in the clinic and has been proven to be 
reasonably safe (Kunwar, Prados et al. 2007). However, a recent phase III trial (PRECISE) 
comparing outcome of adults with recurrent GBM who received CED of IL-13PE38QQR 
with those who were treated with BCNU wafers showed no difference in outcome (Kunwar, 
Chang et al. 2010). The reasons for lack of better benefit from this promising strategy could 
be due to poor catheter placement, inadequate expression of target receptors in the tumor, 
or other unknown factors.  
The problem of drug resistance to alkylating agents has been extensively addressed at Duke 
University Medical Center and is predominantly due to overexpression of alkyl guanine 
alkyltransferase (AGAT) in tumor cells. The cellular enzyme, O6 guanine DNA alkyl 
transferase (AGAT), is responsible for removing the alkyl groups from the O6 -position of 
deoxyguanosine and prevents cross-linking of DNA (Dolan and Pegg 1997). Increased 
expression of this DNA repair protein is the major mechanism of resistance to nitrosoureas 
and other alkylating agents (Dolan and Pegg 1997). O6-Benzylguanine (O6-BG) is a 
modulating agent that demonstrates high affinity for AGAT and effectively enhances 
nitrosourea activity in vitro and in vivo (Dolan and Pegg 1997).  Friedman et al. at Duke 
University Medical Center conducted a phase I trial of O6-BG in patients with malignant 
glioma and determined the optimum biologic dose that depletes tumor tissue of AGAT to be 
100 mg/m2(Friedman, McLendon et al. 1998). This dose of O6-BG has been subsequently 
used in combination with BCNU in a phase I trial in adults with recurrent HGG (Friedman, 
Pluda et al. 2000). The MTD of BCNU when used in this combination was 40 mg/m2 given 
every 6 weeks. However, a phase II trial of this combination in adults with recurrent 
malignant glioma did not demonstrate any objective response, suggesting that elevation of 
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AGAT is not the only mechanism for treatment failure in these patients (Quinn, Dolan et al. 
2001). Treatment failure in this setting could also be related to limitations of achieving 
adequate intratumor drug concentrations due to the lower dose of BCNU. For similar 
reasons, the combination of oral Temozolomide plus O6BG in the clinic has met with limited 
success in both adults and children with recurrent malignant glioma (Warren, Aikin et al. 
2005; Quinn, Jiang et al. 2009).  Since high concentration of a chemotherapeutic agent like 
BCNU can be achieved in tumor through intracavitary application with minimal systemic 
exposure, a recent phase II study at Duke University Medical center explored the use of 
O6BG prior to implantation of Gliadel™ wafers with some improvement in survival (Quinn, 
Jiang et al. 2009). Although defective mismatch repair (MMR) is a putative mechanism for 
resistance to methylating agents like Temozolomide, very few human tumors exhibit MMR 
deficiency (Pollack, Hamilton et al. 2010). Alternatively, excessive base excision repair (BER) 
mediated by overexpression of the enzyme Poly (ADP- Ribose) Polymerase (PARP) is 
another resistance mechanism than can cause failure of Temozolomide therapy irrespective 
of AGAT expression (Palma, Wang et al. 2009). ABT-888 (Olgaparib™, Abbott Laboratories, 
Abbott Park, Illinois, USA) is a potent PARP inhibitor that has shown effective PARP 
depletion in tumors and restores sensitivity to Temozolomide (Palma, Rodriguez et al. 2008; 
Palma, Wang et al. 2009). It is currently undergoing evaluation in combination with 
Temozolomide in adults with malignant glioma and children with recurrent brain tumors.  
6.2 Molecular characteristics and specific biologic therapies 
The molecular characteristics of pediatric HGG is quite different from its adult counterpart. 
Isocitrate dehydrogenase (IDH) 1 and 2 mutations that characterize secondary GBM in adults 
are almost unknown in pediatric tumors (Yan, Parsons et al. 2009; Paugh, Qu et al. 2010). Focal 
PDGFR amplification is a common event as is chromosome 1q gain (Paugh, Qu et al. 2010). 
However, EGFR amplification, EGFR vIII mutation, and PTEN loss are less common (Bax, 
Gaspar et al. 2009; Paugh, Qu et al. 2010). Some of these molecular markers of disease have 
been chosen as targets for inhibition using small molecule protein kinase inhibitors including 
ZD1839 (Iressa™, Astra Zeneca Pharmaceuticals, New Jersey, USA) targeting EGFR and 
STI571 (Gleevec™, Novartis Pharmaceuticals, USA) the PDGF receptor (Pollack, Jakacki et al. 
2007). It is likely that these small molecule inhibitors might have some indirect negative effect 
on tumor angiogenesis by affecting downstream targets that are involved in new blood vessel 
formation (Folkman 2007). Phase I trials of these two drugs have been completed in children 
with newly diagnosed and recurrent HGG (including diffuse pontine glioma) through the 
PBTC but no specific efficacy was observed with either drug (Pollack, Jakacki et al. 2007). 
Bevacizumab, a humanized monoclonal antibody against VEGF, recently gained approval by 
the FDA for treatment of GBM in adults on the basis of impressive responses and 
improvement in overall survival noted in adults with recurrent GBM treated with 
Bevacizumab alone or Bevacizumab plus CPT-11 (Cohen, Shen et al. 2009; Friedman, Prados et 
al. 2009). A PBTC phase II trial of this combination in children with recurrent malignant 
glioma and diffuse pontine glioma however failed to show efficacy in either tumor type 
(Gururangan, Chi et al. 2010). The reasons for the lack of efficacy of Bevacizumab in pediatric 
malignant gliomas are unknown. It is possible that VEGF is not the prime mediator of 
angiogenesis in these tumors. It is also likely that angiogenesis inhibition might be better if it is 
used in newly diagnosed patients and in the setting of minimal disease following initial 
surgical resection. The Children’s Oncology Group is currently doing a phase III study 
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exploring the efficacy of Bevacizumab, vorinostat (Zolinza™, Merck Pharmaceuticals, USA), a 
histone deacetylase inhibitor, or Temozolomide concurrently with radiotherapy followed by 
Bevacizumab plus Temozolomide for 6 months in children newly diagnosed malignant glioma 
(Fouladi M., Cincinnati, OH; 2011; personal communication). Since it is unlikely that these 
drugs will be efficacious as single agents, future studies will address whether small molecule 
protein kinase inhibitors can work additively or synergistically with cytotoxics, other kinase 
inhibitors, and anti-angiogenic agents. 
7. Ependymoma 
Ependymomas are the third most common CNS neoplasm and occur in about 10% of all 
children with brain tumors. The tumor typically arises from the neuroepithelial cells lining 
the ventricles. The incidence of ependymomas is inversely related to age, with the peak 
incidence occurring in children less than 6 years of age (Allen, Siffert et al. 1998). Over 90% 
of all childhood ependymomas are intracranial in location and less than 10% occur in the 
spinal cord. Of the intrancranial tumors, 66% are infratentorial (Figure 5) and 34% 
supratentorial in location. No specific risk factors are associated with ependymomas except 
for the increased frequency of spinal cord ependymomas in patients with neurofibromatosis 
type II. Ependymomas are soft and friable and grayish-red in appearance. Microscopically, 
they are extremely cellular with the tumor cells forming pseudo-rosettes around blood 
vessels. Specific histologic variants include the clear-cell, papillary, myxopapillary, and 
anaplastic (WHO grade III). About 20% of patients with ependymomas have metastatic 
spread of disease either at the time of diagnosis or relapse. 
7.1 Treatment 
The current standard of care for patients with non-metastatic ependymoma includes 
adequate surgical resection followed by focal radiotherapy to the tumor site. Patients who 
present with metastatic disease would require neuraxis irradiation as well. Complete 
surgical resection alone could cure a proportion of patients with grade II ependymoma 
arising in the cerebral hemispheres (Awaad, Allen et al. 1996). Extent of surgical resection 
is directly correlated with outcome and hence a complete resection should be attempted 
either at diagnosis or following initial cytotoxic therapy. Young children with disease 
confined to the infratentorial compartment especially in the cerebello-pontine angle are at 
high risk for post-surgical complications as the tumor encompasses blood vessels and 
cranial nerves in this region (Morris, Li et al. 2009). Aggressive surgery in inexperienced 
hands can result in severe dysphagia, vocal cord paralysis, and ataxia but is usually 
associated with neurologic recovery over a period of several months (Morris, Li et al. 
2009). Focal radiotherapy is usually directed at the tumor bed (gross tumor volume, GTV) 
plus a 1-cm margin (clinical target volume, CTV) with additional corrections for day to 
day variations in patient positioning (planned target volume, PTV) (Merchant, Li et al. 
2009).The dose of radiotherapy should be between 45-60 Gy with conventional 
fractionation and administered over 6 weeks (Merchant, Li et al. 2009). Proton, intensity-
modulated, or 3-D conformal radiotherapy is being increasingly used to avoid injury to 
normal structures including hearing and cognition. Since the majority of recurrences are 
local, there is no specific advantage to using craniospinal radiotherapy in patients with 
non-metastatic disease including those with anaplastic histology (Taylor 2004). The use of  
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Fig. 5. T-1 weighted axial and sagittal images of the brain following gadolinium 
administration in a 15 month old boy showing a uniformly enhancing lesion within the 
fourth ventricle that on histology was found to be a well-differentiated ependymoma. 
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chemotherapy has been found to be ineffective in patients with ependymomas and might 
be explained partly by the over-expression of p-glycoprotein in over 80% of these tumors 
(Chou, Barquin et al. 1996; Bouffet and Foreman 1999). Currently, this modality is used 
mainly in infants (children < 4 years of age) in whom even focal radiotherapy to areas of 
the brain can have devastating consequences on neuro- cognitive function (Duffner, 
Horowitz et al. 1993). Platinum compounds (cisplatin or carboplatin) and 
cyclophosphamide are the most commonly used agents against ependymoma (Duffner, 
Horowitz et al. 1993; Bouffet and Foreman 1999). Although objective responses have been 
observed in some studies, outcome for those who receive chemotherapy plus irradiation is 
similar to those following radiotherapy alone. It is possible that chemotherapy can be 
used upfront in some children to allow for more radical second look surgery following 
tumor shrinkage. Survival for children with ependymoma is between 40-77% at 5 years 
post-treatment. Outcome for children with recurrent tumors remains poor despite salvage 
chemotherapy (Bouffet, Capra et al. 2009). 
The most important prognostic factor in children with ependymoma is the extent of surgical 
resection. Patients who have inadequate tumor resection experience a worse outcome. Other 
poor prognostic factors include young age, infratentorial location of tumor, and avoidance 
of radiotherapy (Kilday, Rahman et al. 2009). Anaplastic tumors have been found to confer 
an independently worse prognosis in a recent meta-analysis of over 2000 patients 
(Rodriguez, Scheithauer et al. 2008) but not in other studies (Messahel, Ashley et al. 2009). It 
is possible that the impact of histopathology on prognosis might be dependent on the inter-
observer differences in assessment of anaplasia amongst neuropathologists (Puget, Grill et 
al. 2009). 
7.2 Molecular characteristics 
It is also worth noting that about 50% of patients relapse after focal radiotherapy for localized 
grade II ependymoma following a gross total resection (Kilday, Rahman et al. 2009). It is clear 
that tumor biology plays an important part in determining prognosis in such apparently low-
risk patients. Recent studies have noted that over-expression of ERBB-2/4 and nucleolin, gain 
of chromosome 1q, and homozygous deletion of the CDKN2A gene are associated with a 
worse prognosis independent of clinical factors (Gilbertson, Bentley et al. 2002; Kilday, 
Rahman et al. 2009; Puget, Grill et al. 2009). On the other hand, gains of chromosomes 9, 15q, 
and 18, and loss of chromosome 6 were associated with excellent survival. Such molecular 
alterations need to be validated in larger studies and might serve as targets for future novel 
biologic therapies and also facilitate identification of a group of patients who have a good 
prognosis who could be successfully managed with conservative treatment 
8. Germ cell tumors 
CNS germ cell tumors in children are rare and constitute about 2-5% of all pediatric brain 
tumors. Intracranial germ cell tumors are typically classified as either germinomas or non-
germinomatous germ cell tumors (NGGCT). The former includes pure germinomas and 
germinomas with syncytiotrophoblastic cells and the latter yolk-sac tumors (secreting 
alpha-fetoprotein, AFP), choriocarcinomas (secreting beta subunit of human chorionic 
gonadotropins, ǃ-HCG), embryonal carcinoma (secreting carcinoembryonic antigen, 
CEA), teratomas (mature and immature), and mixed germ cell tumors (including varying 
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components of germinoma and NGGCT) (Rosenblum, Matsutani et al. 2000). The 
incidence of these tumors is higher in the Asian population (15-18% of all childhood brain 
tumors) compared to western countries (Rosenblum, Matsutani et al. 2000). The peak age 
of onset is 10-12 years of age and occasionally in the second to third decade of life 
(Rosenblum, Matsutani et al. 2000). There is a sex predilection for tumor site and 
histologic type with female predominance for tumors that originate in the suprasellar 
region and NGGCT. CNS germ cell tumors occur commonly in the pineal region (45%), 
suprasellar region (35%), both (10%), and other sites including intraventricular, basal 
ganglia, thalamus, medulla oblongata, and cerebral hemispheres (10%) (Rosenblum, 
Matsutani et al. 2000). Presentation of bifocal tumors is not uncommon and represents 
development of tumors in two independent sites and not metastasis (Figure 6). Presenting 
symptoms in patients with germ cell tumors depend on the location of tumor. Suprasellar 
germ cell tumors can present with isolated diabetes insipidus caused by pituitary stalk 
thickening, hydrocephalus, visual disturbances, delayed growth, or precocious puberty 
(Diez, Balmaceda et al. 1999; Rosenblum, Matsutani et al. 2000). Pineal tumors can cause 
hydrocephalus due to early compression of the aqueduct and paralysis of upward gaze 
and convergence due to pressure on the tectum of the mid-brain (Parinaud’s syndrome). 
Leptomeningeal seeding occurs in about 10-15% of patients and can cause symptoms of 
spinal cord compression due to block disease (Diez, Balmaceda et al. 1999). It is important 
to remember that patients with germinoma can have isolated cerebrospinal fluid 
positivity for malignant cells without any evidence of spinal cord dissemination on 
neuroimaging. 
 
 
Fig. 6. T-1 weighted sagittal image of the brain following gadolinium in an 18-year old black 
male showing enhancing lesions in the suprasellar and pineal region (white arrows) that 
was found to be a pure germinoma on biopsy of the pineal mass 
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Histologically, germinoma consists of a uniform sheet of cells that have vesicular nuclei, 
prominent nucleoli, and a glycogen-rich cytoplasm. Additional features include 
lymphocytic infiltration, and scattered syncytiotrophoblastic cells (Rosenblum, Matsutani et 
al. 2000). Teratomas recapitulate somatic development from the three embryonic germ 
layers with mature forms demonstrating adult tissue including cartilage, bone, and teeth 
and the immature variety composed of primitive neuro-epithelial cells arranged in an 
abortive formation of neural tubes (Rosenblum, Matsutani et al. 2000). Yolk-sac tumors are 
composed of primitive appearing epithelial cells in a loose myxoid matrix and eosinophilic 
hyaline globules immunoreactive for AFP (Rosenblum, Matsutani et al. 2000). The histologic 
diagnosis of a choriocarcinoma requires the identification of cytotrophoblastic and 
syncytiotrophoblastic giant cells that are positive for beta-HCG and human placental 
lactogen (Rosenblum, Matsutani et al. 2000). Embryonal carcinoma consists of large cells 
that proliferate in nests and sheets, forming abortive papillae and embryoid bodies with 
germinal discs and miniature amniotic cavities, large nucleoli, and high mitotic index. The 
cells are positive for cytokeratin and human placental alkaline phosphatase (Rosenblum, 
Matsutani et al. 2000). 
In addition to neuro-imaging studies and biopsy confirmation, patients with intracranial 
germ cell tumors usually have serum and CSF estimated for protein markers including AFP 
and beta-HCG, for diagnosis and assessment of tumor response (Gregory and Finlay 1999). 
If the markers are elevated in CSF samples, diagnosis can be made and treatment initiated 
without the need for a biopsy (Gregory and Finlay 1999). 
8.1 Treatment 
The standard treatment for patients with pure germinoma is radiotherapy (Diez, Balmaceda 
et al. 1999). This tumor is exquisitely sensitive to irradiation and excellent survival has been 
obtained with this modality alone. Germinomas typically spread via the ventricular wall 
and it is extremely important to include the whole ventricular volume (radiotherapy dose 
up to 24 Gy) in addition to the primary site (up to 45 Gy) in the radiation field for patients 
with localized disease and the craniospinal axis (up to 24 Gy) in those with metastatic 
disease (Diez, Balmaceda et al. 1999). The use of 3-D conformal radiotherapy technique can 
minimize long-term side effects of irradiation (Diez, Balmaceda et al. 1999). Using this 
strategy, cure can be achieved in over 90% of these patients (Diez, Balmaceda et al. 1999). 
Germinoma is very responsive to chemotherapy as well with excellent objective responses 
(>90%)reported with single agent cyclophosphamide or carboplatin (Diez, Balmaceda et al. 
1999). In recent years there have been several clinical trials in the United States, Japan, and 
Europe that have attempted to use chemotherapy combinations (carboplatin + etoposide, 
carboplatin + etoposide + bleomycin ± cyclophosphamide, or ifosfamide + carboplatin + 
etoposide) with the aim of avoiding or reducing the dose and extent of radiotherapy and its 
associated neuro-psychologic sequelae on the brain. This strategy has been reasonably 
successful although the progression-free survival with chemotherapy alone is only 50-60% 
(Diez, Balmaceda et al. 1999). However, most of the patients who fail chemotherapy can be 
salvaged with radiotherapy underscoring the importance of the latter modality in the cure 
of patients with germinoma. While some series have indicated that patients with germinoma 
with beta-HCG elevation up to 50 I.U have an inferior outcome, recent reports have 
demonstrated that with adequate doses of radiotherapy these patients do just as well as 
those with pure germinoma (Shibamoto, Takahashi et al. 1997). It must be emphasized that 
the use of chemotherapy alone in patients with germinoma is effective in only a proportion 
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of patients and is not the standard of care (Diez, Balmaceda et al. 1999). Only large 
randomized trials of standard radiotherapy alone vs. chemotherapy plus reduced dose 
irradiation will clearly establish the efficacy of chemotherapy in safely allowing dose and 
field reductions in radiotherapy and whether patients who receive the chemotherapy plus 
reduced dose irradiation will have fewer neuro-cognitive deficits.  
Patients with NGGCT do very poorly with radiotherapy alone with only 20-60% surviving 
progression-free with this modality alone (Diez, Balmaceda et al. 1999). The addition of 
chemotherapy as used for patients with germinoma has improved the survival to around 45 
– 80% (Diez, Balmaceda et al. 1999).  Patients with recurrent germ cell tumors have a poor 
prognosis. A proportion of patients with chemo sensitive disease have been salvaged with 
high-dose chemotherapy and autologous stem cell rescue (Modak, Gardner et al. 1997; Tada, 
Takizawa et al. 1999). 
9. Choroid plexus tumors 
Choroid plexus tumors are rare in children and comprise 2-4% of brain tumors in this 
population (Greenberg 1999) Choroid plexus tumors can either be a choroid plexus 
papilloma (60% - 80%) or carcinoma (20% -40%).(Greenberg 1999). The predominant 
location of these tumors is in the lateral ventricles and less commonly in the III and IV 
ventricles. Choroid plexus tumors that occur in the lateral ventricles are invariably found in 
infants or young children with a median age of diagnosis of 24 months (Greenberg 1999). 
These tumors typically arise from the choroid plexus epithelium and are extremely vascular. 
The histologic findings in a choroid plexus papilloma include a papillomatous component 
lined by single layer of columnar or cuboidal epithelium and a central core of vascular 
stromal tissue and the absence of mitosis and normal tissue invasion. In contrast, choroid 
plexus carcinoma consists of sheets of cells without papillary formation, nuclear atypia and 
pleomorphism, frequent mitoses, and invasion of sub ependymal brain tissue. Children with 
choroid plexus tumors frequently present with hydrocephalus due to mechanical 
obstruction and/or CSF overproduction (Figure 7) (Greenberg 1999). Up to 30% of children 
present with metastatic disease at diagnosis. 
9.1 Treatment 
Surgical resection of choroid plexus papilloma frequently results in long-term cure 
(Greenberg 1999). The management of choroid plexus carcinoma is more complex. While 
adequate surgical resection is the most important determinant of long-term disease control, 
tumors can be extremely large and vascular at diagnosis precluding adequate resection 
without causing excessive blood loss or neurologic damage (Greenberg 1999). In these 
situations, it might be more beneficial to confirm the diagnosis on a limited stereotactic 
biopsy and treat patients with chemotherapy prior to definitive surgical resection 
(Greenberg 1999). The standard chemotherapy regimen used in infants and young includes 
vincristine, cisplatin/carboplatin, cyclophosphamide, and etoposide and can be used in a 
neoadjuvant or adjuvant setting (Greenberg 1999). 
The efficacy of post-operative radiotherapy in patients with choroid plexus carcinoma is 
unclear (Greenberg 1999; Fitzpatrick, Aronson et al. 2002). The need for craniospinal 
irradiation for this disease with a high predilection for neuraxis dissemination argues 
against the use of this modality in young children due to the risk of neuro-cognitive deficits 
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and endocrine sequelae. In general, it appears that the degree of surgical resection seems to 
determine the outcome of patients with choroid plexus carcinoma irrespective of the 
adjuvant chemo/radiotherapy received post-surgery (Fitzpatrick, Aronson et al. 2002) 
 
 
Fig. 7. T-1 weighted axial image of the brain following gadolinium in a 4-month old male 
showing a large uniformly enhancing lesion in the left occipital horn that on biopsy was 
found to be a choroid plexus papilloma with some features of anaplasia 
 
  
Fig. 8. T-1 weighted axial and saggital images following gadolinium contrast in a 4 month 
old white male showing a heterogeneously enhancing  cystic solid mass in the region of the 
right foramen of Lushka and cerebello-pontine angle causing mass effect on the brain stem 
and IV ventricle.  Tumor resection revealed an atypical teratoid rhabdoid tumor  
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10. Atypical teratoid rhabdoid tumors 
Atypical Teratoid Rhabdoid tumor (ATRT) of the CNS is a rare embryonal tumor that occurs 
predominantly in children less than 5 years of age (Rorke, Packer et al. 1996; Oka and 
Scheithauer 1999). Originally described in 1987, this tumor, in the past, had been mistaken 
for and treated as a PNET of the nervous system (Packer, Biegel et al. 2002). In recent years, 
there has been an explosion in knowledge regarding criteria for histologic diagnosis and 
molecular characteristics of the tumor (Packer, Biegel et al. 2002). ATRT constitutes 1-2% of 
CNS malignancies in children with a reported incidence of 1.38 per 100,000 children/year 
(Woehrer, Slavc et al. 2010). The tumors can occasionally be familial due to a rhabdoid 
tumor predisposition syndrome (Janson, Nedzi et al. 2006). The median age at diagnosis is 
2.1 years and 90% of patients are less than 5 years at diagnosis (Oka and Scheithauer 1999). 
Less than 10% of patients are in older children up to the ages of 10-15 years (Oka and 
Scheithauer 1999) (figure 8). The commonest location is in the posterior fossa in over 60% of 
cases; other sites include the cerebral hemispheres, suprasellar region, third ventricle, pineal 
region, and spinal cord (Rorke, Packer et al. 1996; Oka and Scheithauer 1999). There is a high 
predilection for CSF dissemination in about 30% of cases (Oka and Scheithauer 1999). 
Histologically the tumor consists of sheets of rhabdoid cells, areas that resemble classic 
PNET along with mesenchymal and epithelial differentiation (Rorke, Packer et al. 1996). The 
rhabdoid cell has an eccentric round nucleus, prominent nucleolus, and a plump cell body. 
Immunohistochemical staining is positive for vimentin, cytokeratin, and epithelial 
membrane antigen. Staining for INI-1 gene product can be done using the BAF-47 antibody 
and absence of INI-1 expression in the nucleus is confirmatory for the presence of ATRT. 
10.1 Treatment 
Treatment of ATRT has traditionally been surgical resection followed by intensive 
chemotherapy and irradiation. However, most infants with ATRT have been reported to 
succumb to the disease with progression-free survival of < 20% despite treatment. However, 
a recent study from Dana Farber Cancer Institute in Boston, MA, has reported a more 
favorable outcome of 53% 2-year PFS with intensive chemotherapy plus irradiation in young 
children with ATRT (Chi, Zimmerman et al. 2009). Older patients with ATRT seem to do 
better than infants with the same intensive multimodality treatment (Tekautz, Fuller et al. 
2005). 
10.2 Molecular characteristics and biologic therapies 
The molecular characteristic of this tumor has been well delineated in recent years. The tumor 
typically demonstrates monosomy of chromosome 22 that results in deletion of the tumor 
suppressor gene HSN5-INI1 located on chromosome 22q11.2 (Biegel, Kalpana et al. 2002). 
Robust pre-clinical models have clearly demonstrated that deletion of the HSN5-INI1 gene is 
directly responsible for tumor development and restoration of the gene in the tumor cells can 
cause tumor regression. INI1 mediates tumor suppression by recruiting HDAC to the cyclin D-
1 promoter and preventing cyclin D1 expression (Tsikitis, Zhang et al. 2005). Cyclin D-1 
overexpression is commonly seen in CNS ATRTs and the combination of Fenretinide plus 
Tamoxifen has been shown to synergistically down regulate cyclin D-1 expression and cause 
tumor regression in animals bearing ATRT xenografts (Alarcon-Vargas, Zhang et al. 2006). It 
remains to be seen if this strategy would work in children with CNS ATRT. 
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